GREENWICH LIFESCIENCES, INC. Shares Issued
GREENWICH LIFESCIENCES, INC. (GLSI) had Shares Issued of 14.68 million shares as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Common Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:CommonStockSharesIssued · last filed 2026-08-11
- 2026-06-30: Common Stock, Shares, Issued 14.68M shares.
- 2026-03-31: Common Stock, Shares, Issued 14.67M shares.
- 2025-12-31: Common Stock, Shares, Issued 14.30M shares.
- 2025-09-30: Common Stock, Shares, Issued 13.79M shares.
| Period end | Common Stock, Shares, Issued |
|---|---|
| 2026-06-30 | 14.68M shares 10-Q · filed 2026-08-11 |
| 2026-03-31 | 14.67M shares 10-Q · filed 2026-06-04 |
| 2025-12-31 | 14.30M shares 10-Q · filed 2026-08-11 |
| 2025-09-30 | 13.79M shares 10-Q · filed 2025-11-14 |
| 2025-06-30 | 13.47M shares 10-Q · filed 2025-08-14 |
| 2025-03-31 | 13.19M shares 10-Q · filed 2025-05-20 |
| 2024-12-31 | 13.15M shares 10-K · filed 2026-06-01 |
| 2024-09-30 | 13.14M shares 10-Q · filed 2024-11-14 |
| 2024-06-30 | 13.07M shares 10-Q · filed 2024-08-14 |
| 2024-03-31 | 12.88M shares 10-Q · filed 2024-05-20 |
| 2023-12-31 | 12.85M shares 10-K · filed 2025-04-15 |
| 2023-09-30 | 12.85M shares 10-Q · filed 2023-10-19 |
| 2023-06-30 | 12.85M shares 10-Q · filed 2023-08-21 |
| 2023-03-31 | 12.85M shares 10-Q · filed 2023-05-22 |
| 2022-12-31 | 12.85M shares 10-K · filed 2024-04-15 |
| 2022-09-30 | 12.85M shares 10-Q · filed 2022-11-14 |
| 2022-06-30 | 12.77M shares 10-Q · filed 2022-08-15 |
| 2022-03-31 | 12.95M shares 10-Q · filed 2022-05-20 |
| 2021-12-31 | 13.15M shares 10-K · filed 2023-03-31 |
| 2021-09-30 | 12.99M shares 10-Q · filed 2021-11-15 |
| 2021-06-30 | 12.92M shares 10-Q · filed 2021-08-13 |
| 2021-03-31 | 12.85M shares 10-Q · filed 2021-05-20 |
| 2020-12-31 | 12.70M shares 10-K · filed 2022-03-21 |
| 2020-09-30 | 11.97M shares 10-Q · filed 2020-11-16 |
| 2019-12-31 | 8.46M shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |